Clinical Trials Arena on MSN
Parkinson’s stem cell therapy demonstrates promise in Phase II trial
This therapy is one of a few drugs in mid-to-late-stage development for Parkinson’s that has displayed disease-modifying ...
Stem cell therapy offers a minimally invasive alternative to joint replacement surgery, with recovery times of just one to two weeks compared to months for major surgery Clinical studies show varying ...
When the CEO of Nvidia talks, decision-makers listen, from investors to business executives to Nobel Prize committees. Ever since Jensen Huang observed six months ago that “for the first time in human ...
Every 40 seconds, someone in the United States has a stroke. For survivors of the most common type of stroke, called an ischemic stroke, only about 5 percent fully recover. Most others suffer from ...
Clinical Trials Arena on MSN
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron ...
Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase 1 ...
A new stem cell therapy has repaired blinding damage to the cornea in 93% of patients in an early clinical trial. However, severe injuries, such as those caused by chemical burns or infections, can ...
ORLANDO, Fla — Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. Of a total 17 patients who received a ...
Evelyn Quartey carries the sickle cell trait, as did her ex-husband and first son, Emmanuel, who passed away from Sickle Cell Disease in 2009 at 7. Her younger son Gerald had been diagnosed with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results